Microinvasive Fungal Rhinosinusitis: Proposal of a New Subtype in the Classification

Min Young Seo1,2, Hyeri Seok3,4, Seung Hoon Lee1

  • 1Department of Otorhinolaryngology-Head and Neck Surgery, Korea University College of Medicine, Korea University Ansan Hospital, Ansan 15355, Korea.

Abstract

Insights

Fungal rhinosinusitis with mucosal invasion, distinct from fungal balls, may require a new classification as microinvasive FRS. This condition, identified in 13 patients, showed no recurrences after treatment.

Area of Science:

  • Otolaryngology
  • Mycology
  • Pathology

Background:

  • Current fungal rhinosinusitis (FRS) criteria do not classify mucosal invasion.
  • Clinical data on FRS with mucosal invasion are limited.
  • This study presents a 25-year experience with fungal balls exhibiting mucosal invasion, not fitting existing FRS classifications.

Purpose of the Study:

  • To describe the clinical and pathological characteristics of fungal balls with mucosal invasion.
  • To evaluate the outcomes of surgical and antifungal treatment for this condition.
  • To propose a potential new classification for microinvasive FRS.

Main Methods:

  • Retrospective review of 1318 patients with FRS undergoing endoscopic surgery.
  • Analysis of medical charts and pathology reports for 13 patients with fungal balls and mucosal invasion without tissue invasion.
  • Histopathologic identification of fungal species and assessment of invasion patterns.

Main Results:

  • All identified fungi were *Aspergillus* species.
  • Fungal balls were primarily located in the maxillary and sphenoid sinuses.
  • Median age at diagnosis was 67 years; 9 women and 4 men. Five patients had comorbidities and received antifungal therapy.
  • No recurrences were observed during a median follow-up of 30 months.

Conclusions:

  • Fungal rhinosinusitis with mucosal invasion represents a distinct entity from fungal balls and invasive FRS.
  • A new classification, 'microinvasive FRS', is proposed for fungal balls with mucosal invasion but no vascular invasion.
  • Adjuvant antifungal treatment may benefit immunocompromised patients with microinvasive FRS.